Immunotherapy with anti-CD20 compounds (Q35213332)

7 August 2017

1 reference

title

Immunotherapy with anti-CD20 compounds (English)

1 reference

7 August 2017

1 reference

Christoph von Schilling

series ordinal

1 reference

7 August 2017

publication date

1 June 2003

1 reference

Seminars in Cancer Biology

7 August 2017

published in

1 reference

7 August 2017

1 reference

7 August 2017

1 reference

7 August 2017

page(s)

211-222

1 reference

Molecular cloning of a t(11;14)(q13;q32) translocation breakpoint centromeric to the BCL1-MTC.

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Composition of precursor B-cell compartment in bone marrow from patients with X-linked agammaglobulinemia compared with healthy children.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Molecular mechanisms regulating CD19, CD20 and CD22 gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Low level CD20 expression on T cell malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Cd20 (pan‐B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary struc

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Mice carrying a CD20 gene disruption

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

CD20: a regulator of cell-cycle progression of B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

CD20 monoclonal antibodies down‐regulate IgM at the surface of B cells

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Engagement of CD20 suppresses apoptosis in germinal center B cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Activation of the calcium-permeable cation channel CD20 by alpha subunits of the Gi protein

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

The association between CD20 and Src-family Tyrosine kinases requires an additional factor

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rapid Redistribution of CD20 to a Low Density Detergent-insoluble Membrane Compartment

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

CD20-mediated apoptosis: signalling through lipid rafts

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

CD20-induced B cell death can bypass mitochondria and caspase activation.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Treatment of Waldenström's macroglobulinemia with rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Variation in gene expression patterns in follicular lymphoma and the response to rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Chronic B cell malignancies and bone marrow microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

CD20-negative relapse after (131)I-anti-CD20 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

In vivo purging with rituximab prior to collection of stem cells for autologous transplantation in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab: enhancing stem cell transplantation in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Complement activation plays a key role in the side-effects of rituximab treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab-induced vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Engineered antibodies with increased activity to recruit complement

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results

1 reference

https://api.crossref.org/works/10.1016%2FS1044-579X%2803%2900018-X

7 January 2021

10.1016/S1044-579X(03)00018-X

Identifiers

DOI

1 reference

release_yo6se36srrelxiy7rcyy7ee6da

7 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yo6se36srrelxiy7rcyy7ee6da

24 November 2022

mapped directly with Wikidata item

1 reference